Indometacin farnesil

Indometacin farnesil

Indometacin farnesil is a pharmaceutical compound recognized by its INN. Acting as a prodrug, it serves as a precursor to the more widely recognized non-steroidal anti-inflammatory drug (NSAID) known as indometacin.

Overview

The primary rationale behind the creation of indometacin farnesil was to circumvent some of the adverse effects commonly associated with indometacin. This was achieved by esterifying the carboxyl group present on indometacin using farnesol, a process that can reduce the potential for certain side-effects.

Approval and Availability

Japan

Indometacin farnesil received its initial approval in Japan in 1991. It is commercially available in the country under the trade name Infree.

Indonesia

In addition to Japan, indometacin farnesil is also available in Indonesia. Here, the medication can be found under the trade name Dialon.

Pharmacological Mechanism

As a prodrug, indometacin farnesil is biologically inactive in its administered form. Once inside the body, however, it is metabolized to release the active NSAID, indometacin. This transformation allows for the therapeutic effects of indometacin to be realized, while the esterification with farnesol aims to mitigate the drug's side-effects.

See Also

• Non-steroidal anti-inflammatory drug
• Prodrug
• Indometacin
• Farnesol

External links

• Infree prescribing information from Eisai Co.

Drug groups | Encyclopedia | Dictionary | Cancer drugs | OTC | Alternative meds | Drugs | Medications A-Z | FDA approved products | Portal:Pharmacology

‎